ES2187520T3 - Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina. - Google Patents

Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.

Info

Publication number
ES2187520T3
ES2187520T3 ES94910445T ES94910445T ES2187520T3 ES 2187520 T3 ES2187520 T3 ES 2187520T3 ES 94910445 T ES94910445 T ES 94910445T ES 94910445 T ES94910445 T ES 94910445T ES 2187520 T3 ES2187520 T3 ES 2187520T3
Authority
ES
Spain
Prior art keywords
pct
cytoquine
muramil
peptide
association
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94910445T
Other languages
English (en)
Inventor
Louis Chedid
Georges Bahr
Pierre Lefrancier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Vacsyn SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr
Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr
Application filed by Vacsyn SA filed Critical Vacsyn SA
Application granted granted Critical
Publication of ES2187520T3 publication Critical patent/ES2187520T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMPOSICION QUE ASOCIA, PARA SU APLICACION EN TERAPIA HUMANA, AL MENOS UNA CITOQUINA NATURAL O RECOMBINANTE, PREFERENTEMENTE HUMANA, CON LA MENOS UN MURAMILPEPTIDO ELEGIDO ENTRE LOS QUE, CUANDO SON ADMINISTRADOS "IN VIVO" EN ASOCIACION CON UN INTERFERON, INDUCEN TAMBIEN LA PRODUCCION INCREMENTADA IN VIVO DE UN ANTAGONISTA IL-1 RA DEL RECEPTOR DE LA INTERLEUQUINA I Y, PREFERENTEMENTE, NO INDUCEN UN CRECIMIENTO DE LAS CITOQUINAS IL-1, TNF Y IL-8. SE PUEDE UTILIZAR PARA TERAPIAS ANTIVIRALES, ANTITUMORALES Y/O PARA FAVORECER UNA RECONSTITUCION DEL SISTEMA HEMATOPOIETICO, PARTICULARMENTE EN PERSONAS CUYO SISTEMA INMUNITARIO ES O SE HA VUELTO DEFICIENTE.
ES94910445T 1993-03-19 1994-03-21 Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina. Expired - Lifetime ES2187520T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9303230A FR2702659B1 (fr) 1993-03-19 1993-03-19 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FR9303787A FR2703251B3 (fr) 1993-03-31 1993-03-31 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .

Publications (1)

Publication Number Publication Date
ES2187520T3 true ES2187520T3 (es) 2003-06-16

Family

ID=26230187

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94910445T Expired - Lifetime ES2187520T3 (es) 1993-03-19 1994-03-21 Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.

Country Status (11)

Country Link
US (1) US5932208A (es)
EP (1) EP0689449B1 (es)
JP (1) JP3723206B2 (es)
AT (1) ATE226828T1 (es)
AU (1) AU6285694A (es)
CA (1) CA2157758A1 (es)
DE (1) DE69431620T2 (es)
DK (1) DK0689449T3 (es)
ES (1) ES2187520T3 (es)
PT (1) PT689449E (es)
WO (1) WO1994021275A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6267968B1 (en) * 1995-04-07 2001-07-31 Vacsyn S.A. MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
ES2312179T3 (es) 1996-12-06 2009-02-16 Amgen Inc. Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
CN1441676B (zh) 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
FR2809106A1 (fr) * 2000-05-17 2001-11-23 Istac Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
EP2295081B1 (en) 2001-06-26 2018-10-31 Amgen Inc. Antibodies to OPGL
WO2003002187A2 (en) * 2001-06-26 2003-01-09 Photomed Technologies, Inc. Multiple wavelength illuminator
EP2168598A1 (en) * 2001-09-28 2010-03-31 Purdue Research Foundation Method of Treatment Using Ligand-Immunogen Conjugates
US20030097409A1 (en) * 2001-10-05 2003-05-22 Hungchou Tsai Systems and methods for securing computers
KR101317045B1 (ko) 2002-09-06 2013-10-16 암젠 인코포레이티드 치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7546638B2 (en) * 2003-03-18 2009-06-09 Symantec Corporation Automated identification and clean-up of malicious computer code
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
KR20070084270A (ko) * 2004-11-17 2007-08-24 바이오마린 파머수티컬 인크. 안정한 정제 제형물
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN101918018B (zh) 2007-11-14 2012-12-05 再生医药有限公司 使用白介素-1受体拮抗剂作为骨髓保护剂的方法
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
WO2018022982A1 (en) 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
US12403181B2 (en) 2018-08-13 2025-09-02 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
EP4411592B1 (de) 2023-02-06 2025-04-02 Sick Ag Verfahren zum lesen eines optischen codes und optoelektronischer codeleser

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) * 1986-08-13 1987-12-31 Takeda Chemical Industries Ltd Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination

Also Published As

Publication number Publication date
DE69431620T2 (de) 2003-07-03
ATE226828T1 (de) 2002-11-15
EP0689449A1 (fr) 1996-01-03
PT689449E (pt) 2003-03-31
DE69431620D1 (de) 2002-12-05
CA2157758A1 (en) 1994-09-29
JPH08511235A (ja) 1996-11-26
US5932208A (en) 1999-08-03
EP0689449B1 (fr) 2002-10-30
JP3723206B2 (ja) 2005-12-07
DK0689449T3 (da) 2003-03-03
AU6285694A (en) 1994-10-11
WO1994021275A1 (fr) 1994-09-29

Similar Documents

Publication Publication Date Title
ES2187520T3 (es) Composiciones para aplicacion en terapeutica humana, caracterizadas por la asociacion de un muramil-peptido a una citoquina.
Stern et al. Interleukin-12 an integral cytokine in the immune response
Banks et al. Interleukin 12: a new clinical player in cytokine therapy
Trinchieri et al. Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation
CA1288694C (en) Process for treatment of diseases
Lacey et al. IL-1-induced murine osteoblast IL-6 production is mediated by the type 1 IL-1 receptor and is increased by 1, 25 dihydroxyvitamin D3.
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
NO965621L (no) Nye hIL-4-mutantproteiner som antagonister eller partielle agonister for det humane interleukin 4
Lefort et al. IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells
BR9910505A (pt) Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
DK0613499T3 (da) Humame IT-4-mutantproteiner
BRPI0415290A (pt) uso terapêutico de variantes de quimiocina
Morhenn The etiology of lichen planus: a hypothesis
ATE442387T1 (de) Dimerisierter t-zell rezeptor fragment, dessen zusammensetzungen und verwendung
IT1276555B1 (it) Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni
ATE159172T1 (de) Peptide und deren verwendung
DK0742720T3 (da) Co-indgivelse af interleukin-3-mutantpolypeptider med CSF'er til produktion af hæmatopoietiske celler med multi-afstamning
BR9713096A (pt) Lactação bovina associada à proteìna imunotrópica (cd14), gene codificado e aplicação na ativação de célula b
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
EP0905234A3 (en) Allelic variant of human STAT3
WO2000009150A3 (en) Cytokine and cytokine receptor, agonist, antagonist and/or antibody combination for therapeutic use
Miller et al. Cytokine priming reduces dependence on TNF-R2 for TNF-α-mediated induction of macrophage nitric oxide generation
Rouse Use of heat-pressed leucite reinforced porcelain in “difficult” veneer cases: A clinical report